Septerna, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 44 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.05B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves’ disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women’s health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
Details
| Name | Septerna, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 123 |
| Founded | 2022 |
| Ipo Date | 2024-10-25 |
| Ceo | Jeffrey Finer |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 18.00 |
| Isin | US81734D1046 |
| Cusip | 81734D104 |
| Cik | 1984086 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Jeffrey T. Finer M.D., Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Elizabeth P. Bhatt M.B.A., M.S. | President and Chief Operating Officer |
| Gilbert M. Labrucherie C.F.A., J.D. | Chief Financial Officer |
| Dr. Robert J. Lefkowitz M.D. | Co-Founder and Member of Cross-Functional Scientific and Drug Discovery Advisory Board |
| Dr. Arthur Christopoulos BPHARM, Ph.D. | Co-Founder and Member of Cross-Functional Scientific and Drug Discovery Advisory Board |
| Dr. Patrick Sexton Ph.D. | Co-Founder and Member of Cross-Functional Scientific and Drug Discovery Advisory Board |
| Richard Hansen Ph.D. | Vice President of Technology |
| Mark A. Wilson J.D. | Chief Legal Officer |
| George Xu Ph.D. | Senior Director of Corporate Development and Portfolio Strategy |
| Samira Shaikhly | Chief People Officer |
Contact
| Address | 250 East Grand Avenue, South San Francisco, California 94080, United States |
| Phone | 650 338 3533 |
| Website | https://www.septerna.com |